LEI 5493003EJXH8XA8L9095

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

Group parent: GSK PLC

Awards tracked

53

Value

€33.48M

Countries

GB

Download sample CSV

Contract awards & public grants

HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2026-07-14

—

MOlecular BIodiscovery for Life sciences InTerdiscplinarY innovation → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2026-07-02

—

FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2026-06-02

—

Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2026-05-04

—

101253015 - GUIDE-AI - GUIDE-AI GUIDING YOUR TREATMENT WITH CURRENT EVIDENCE → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

IMI - Innov.Health Initiative · GB · Grant · 2026-01-01

€4.9M

European Novel Drug research to Address Microbial infections and drug Resistance → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2025-12-17

—

GUIDE-AI – Guiding your treatment with current evidence → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2025-12-17

—

Patient Relevant Osteoarthritis endpoints using Big data Evaluation → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2025-12-02

—

101219324 - PROBE - PATIENT RELEVANT OSTEOARTHRITIS ENDPOINTS USING BIG DATA EVALUATION → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

IMI - Innov.Health Initiative · GB · Grant · 2025-12-01

€14M

Doctoral Network on Strains, Diagnostics and Variants → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2025-06-23

—

101191967 - GREG - TESTING, IMPROVING, AND CO-CREATING GUIDANCE AND TOOLS FOR REAL WORLD EVIDENCE GENERATION IN EUROPE AND USE FOR DECISION-MAKING IN → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

IMI - Innov.Health Initiative · GB · Grant · 2025-05-01

€13.3M

Testing, improving, and co-creating Guidance and Tools for Real World Evidence Generation in Europe and use for Decision-Making in Europe: GREG → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2025-04-28

—

Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT) → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2024-12-16

—

Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2024-12-05

—

REpresentative Clinical Research - ADvancing Inclusivity in Europe → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2024-12-05

—

Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2024-11-12

—

Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2024-07-26

—

FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2021-10-11

—

Prioritisation and Risk Evaluation of Medicines in the EnviRonment → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2020-06-24

—

Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2020-04-16

—

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-12-17

—

PharmaLedger → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-12-16

—

Collaboration for Prevention and Treatment of MDR Bacterial Infections → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-11-27

—

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-08-22

—

Short linear interaction motifs as specificity determinants in the ubiquitin system – discovery, mechanisms and therapeutic opportunities → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-08-09

€85,899

Antibiotic Distribution and Recovery in Tissue → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-06-25

—

MachinE Learning Ledger Orchestration for Drug DiscoverY → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-05-22

—

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed w → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-05-06

—

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2019-04-23

—

FAIRplus → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-12-18

—

NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-12-18

—

Multiphoton Microscopy and Ultrafast Spectroscopy: Imaging meets Quantum → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-08-30

€303,173

The GetReal Initiative → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-06-26

—

conect4children (COllaborative Network for European Clinical Trials For Children) → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-06-22

—

Ensuring the future of EUPATI beyond 2020 → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-06-21

—

Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-06-21

—

Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medici → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2018-06-04

—

Rheuma Tolerance for Cure → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2017-08-25

—

Light-driven sustainable biocatalysis training network → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2017-08-02

—

Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2017-03-10

—

Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2017-01-30

—

Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2016-12-22

—

INternational Smart Collaborative Open-access hybrid Printed Electronics pilot line → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2016-11-07

€323,750

Directed Protein Evolution for Synthetic Biology and Biocatalysis → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2016-08-31

—

Graphene-based disruptive technologies → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2016-03-03

€77,281

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2015-12-07

—

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2015-09-02

—

FRAGments training NETwork → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2015-08-11

—

New Diagnostics for Infectious Diseases: “ND4ID” → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2015-07-31

—

Targeted small-molecule Stabilisation of Protein-Protein Interactions → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2015-07-20

—

Theoretical Chemistry and Computational Modelling → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2014-12-16

—

The next generation epigenetic medicine for inflammation → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2014-12-04

€273,288

Robust and affordable process control technologies for improving standards and optimising industrial operations → GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

European Commission · GB · Grant · 2014-11-11

€223,750

Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.